To optimize return on investment, Inorbit aims to develop candidate drugs up to Phase IIb stage, before offering them for out-licensing for further development and marketing. Inorbit will also pursue alliances at earlier stages, i.e. candidate drug selection stage. This will generate revenues to facilitate in house drug discovery and development projects, further mature the pipeline and reduce the need for additional investment.

If we raised your interest, please contact us to discuss the opportunity.